Invega Sustenna: the monthly paliperidone injection

Invega Sustenna is the brand name for paliperidone palmitate, a once-monthly long-acting injectable (LAI) antipsychotic. It is approved by the FDA for schizophrenia and schizoaffective disorder. Its appeal is simple: instead of remembering a pill every day, the patient and prescriber agree on one injection every month, and the medication is delivered slowly into the bloodstream from a depot in the muscle.

What paliperidone is

Paliperidone is the active metabolite of risperidone — the molecule the body produces when it processes risperidone in the liver. It is a second-generation antipsychotic with strong serotonin 5-HT2A and dopamine D2 receptor blockade. As the body's "downstream" version of risperidone, paliperidone has a similar clinical profile but a slightly different metabolism and a slightly cleaner adverse-effect signature.

How the depot works

Invega Sustenna uses a proprietary nanocrystal technology: paliperidone palmitate (a fat-soluble form of paliperidone) is suspended in an aqueous medium and injected into the deltoid (shoulder) or gluteal (buttock) muscle. The crystals dissolve slowly, releasing paliperidone into the bloodstream over approximately 4 weeks. Once steady state is reached, blood levels are far more even than with daily oral medication, with no morning peaks or evening troughs.

The initiation schedule

Unlike most other LAIs, Invega Sustenna can be started without a long oral overlap. The standard initiation uses two loading doses — a higher dose on day 1, then a second dose about a week later (commonly day 8) — both given in the deltoid. After that, monthly maintenance doses are given every 4 weeks (with a small window). This loading schedule is designed to bring blood levels up quickly enough to allow most patients to start the LAI without needing weeks of concurrent oral dosing — though the prescriber's plan always takes priority.

Dosing intervals and the missed-dose window

Maintenance injections are scheduled every 4 weeks but, per FDA labelling, can typically be given a few days early or late without disrupting blood levels. Specific catch-up protocols depend on how many days have passed since the last dose and what dose the patient was on; this decision belongs to the prescriber and the manufacturer's labelling.

Who Invega Sustenna is for

The biggest single use case for any antipsychotic LAI is adherence support. Daily oral antipsychotics are easy to forget; a forgotten week often translates into a relapse. LAIs reduce that risk by removing the daily decision. Studies consistently show that LAIs reduce hospitalisations and relapses compared with oral antipsychotics in patients who have struggled with adherence.

Common reasons a prescriber may suggest Invega Sustenna:

• Past relapses linked to missing oral medication
• Difficulty with daily routine (homelessness, cognitive issues, substance use)
• Patient preference for monthly dosing
• Stable response to oral paliperidone or risperidone

Side effects

The side effect profile of Invega Sustenna is essentially the side effect profile of paliperidone (and risperidone), with some additional injection-site issues:

• Hyperprolactinaemia — paliperidone raises prolactin substantially. Can cause irregular periods, breast tenderness or discharge, sexual dysfunction.
• EPS — moderate risk; akathisia is the most common (see EPS guide)
• Weight gain and metabolic effects — moderate, less than olanzapine but real
• Sedation — mild to moderate
• Orthostatic hypotension — modest
• Tardive dyskinesia with long-term use, though risk is lower than with first-generation antipsychotics

Injection-site reactions

• Pain at the injection site for 1 to 3 days after the shot
• Swelling or a small lump (usually resolves)
• Mild bruising
• Rare nodules with prolonged use

Alternating sides at each injection and using the gluteal site for maintenance can reduce these issues.

Practical questions worth asking your prescriber

• How long should I stay on oral medication after starting the injection?
• Will the dose be the same long-term, or will we adjust it?
• What signs of relapse should I watch for as the next injection approaches?
• What's the plan if I have to miss an injection (travel, illness)?
• If I tolerate the monthly dose well, am I a candidate for the longer-interval form (Invega Trinza every 3 months)?

The bigger picture

For people whose biggest single risk factor is missing doses, an LAI like Invega Sustenna can be transformative. The data on relapse and rehospitalisation reduction with LAIs is strong — see, for example, the systematic reviews summarised by NICE and SAMHSA. Invega Sustenna is not the only option; Abilify Maintena, Risperdal Consta, Aristada, and Perseris are alternatives. The right choice depends on which oral antipsychotic the patient has tolerated best, the dosing interval, the injection route (IM versus subcutaneous), and a careful conversation with the prescriber.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.